Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 615-621

  Yee, Leland J ^a,b   Im, KyungAh ^a   Wahed, Abdus S ^a   Bugawan, Teodorica ^c   Li, Jia ^c   Rhodes, Shannon L ^d   Erlich, Henry ^c   Rosen, Hugo R ^e   Liang, T Jake ^f   Yang, Huiying ^d,g  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL;

ALLELES; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; ETHNIC GROUPS; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; RIBAVIRIN; VIRAL LOAD;

EID: 59749101989     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00947-08     Document Type: Article

References (31)

1. Aikawa, T., M. Kojima, H. Onishi, R. Tamura, S. Fukuda, T. Suzuki, F. Tsuda, H. Okamoto, Y. Miyakawa, and M. Mayumi. 1996. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J. Med. Virol. 49:274-278.
2. Alter, M., D. Kruszon-Moran, O. Nainan, G. McQuillan, F. Gao, L. Moyer, R. Kaslow, and H. Margolis. 1999. Prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556-562.
3. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946-952.
4. Brown, H., and R. Prescott. 1999. Applied mixed models in medicine. John Wiley & Sons, Inc., New York, NY.
5. Conjeevaram, H. S., M. W. Fried, L. J. Jeffers, N. A. Terrault, T. E. Wiley-Lucas, N. Afdhal, R. S. Brown, S. H. Belle, J. H. Hoofnagle, D. E. Kleiner, and C. D. Howell. 2006. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470-477.
6. Cramp, M. E., S. Rossol, S. Chokshi, P. Carucci, R. Williams, and N. Naoumov. 2000. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346-355.
7. Ferenci, P., M. W. Fried, M. L. Shiffman, C. I. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, M. Chaneac, and K. R. Reddy. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 43:425-433.
8. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
9. Herrmann, E., J. H. Lee, G. Marinos, M. Modi, and S. Zeuzem. 2003. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351-1358.
10. Higashi, Y., N. Kamikawaji, H. Suko, and M. Ando. 1996. Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J. Gastroenterol. Hepatol. 11:241-246.
11. Hong, X., R. B. Yu, N. X. Sun, B. Wang, Y. C. Xu, and G. L. Wu. 2005. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J. Gastroenterol. 11:7302-7307.
12. Howell, C. D., L. S. Jeffers, W. Cassidy, K. R. Reddy, S. Hu, and J. S. Lee. 2006. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J. Viral Hepat. 13:371-376.
13. Jeffers, L. J., W. Cassidy, C. D. Howell, S. Hu, and K. R. Reddy. 2004. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:1702-1708.
14. Kaplan, D. E., K. Sugimoto, F. Ikeda, J. Stadanlick, M. Valiga, K. Shetty, K. R. Reddy, and K. M. Chang. 2005. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 41:1365-1375.
15. Kuzushita, N., N. Hayashi, T. Moribe, K. Katayama, T. Kanto, S. Nakatani, T. Kaneshige, T. Tatsumi, A. Ito, K. Mochizuki, Y. Sasaki, A. Kasahara, and M. Hori. 1998. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 27:240-244.
16. Layden-Almer, J. E., and T. J. Layden. 2003. Viral kinetics in hepatitis C virus: special patient populations. Semin. Liver Dis. 23(Suppl. 1):29-33.
17. Layden-Almer, J. E., R. M. Ribeiro, T. Wiley, A. S. Perelson, and T. J. Layden. 2003. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37:1343-1350.
18. Layden, J. E., and T. J. Layden. 2002. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 35:967-970.
19. Layden, J. E., T. J. Layden, K. R. Reddy, R. S. Levy-Drummer, J. Poulakos, and A. U. Neumann. 2002. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J. Viral Hepat. 9:340-345.
20. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
21. Nakajima, A., N. Matsuhashi, T. Kodama, Y. Yazaki, M. Takazoe, and A. Kimura. 1995. HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology 109:1462-1467.
22. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
23. Pritchard, J. K., M. Stephens, and P. Donnelly. 2000. Inference of population structure using multilocus genotype data. Genetics 155:945-959.
24. Pritchard, J. K., M. Stephens, N. A. Rosenberg, and P. Donnelly. 2000. Association mapping in structured populations. Am. J. Hum. Genet. 67:170-181.
25. Rhodes, S. L., H. Erlich, K. A. Im, J. Wang, J. Li, T. Bugawan, L. Jeffers, X. Tong, X. Su, H. R. Rosen, L. J. Yee, T. J. Liang, and H. Yang. 2008. Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun. 9:328-333.
26. Rosen, H. R., S. J. Weston, K. Im, H. Yang, J. R. Burton, Jr., H. Erlich, J. Klarquist, and S. H. Belle. 2007. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 46:350-358.
27. Singer, J. D., and J. B. Willett. 2003. Applied longitudinal data analysis. Oxford University Press, New York, NY.
28. Tang, K. H., E. Herrmann, H. Cooksley, N. Tatman, S. Chokshi, R. Williams, S. Zeuzem, and N. V. Naoumov. 2005. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J. Hepatol. 43:776-782.
29. Yee, L. J. 2004. Host genetic determinants in hepatitis C virus infection. Genes Immun. 5:237-245.
30. Yee, L. J., Y. M. Tang, D. E. Kleiner, D. Wang, K. Im, A. Wahed, X. Tong, S. Rhodes, X. Su, R. M. Whelan, R. J. Fontana, M. G. Ghany, B. Borg, T. J. Liang, and H. Yang. 2007. Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology 46:74-83.
31. Yoshitake, S., A. Kimura, M. Okada, T. Yao, and T. Sasazuki. 1999. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens 53:350-358.